Department of Dermatology & STD, Patna Medical College & Hospital, Patna, India.
Endocrinology Clinic Srikrishna Puri, Patna, India.
Australas J Dermatol. 2024 Aug;65(5):437-443. doi: 10.1111/ajd.14306. Epub 2024 May 19.
Female-pattern hair loss (FPHL) is characterized by decreased scalp hair density, thinning of hair shafts, and progressive miniaturization of hair follicles.
To compare the safety and efficacy of spironolactone versus bicalutamide in female pattern hair loss [FPHL].
The study design was retrospective, and all eligible females aged between 18 years and 50 years with FPHL were included. We identified 120 patients from our database who fulfilled the inclusion and exclusion criteria, and patients were then categorized into two groups, Group A comprising patients who were taking 100 mg of spironolactone once daily and Group B comprising patients who were taking 50 mg of bicalutamide once daily along with topical minoxidil 2% in both groups. Patient were analysed at approximately at 24 weeks from the commencement of the treatment.
Mean reduction in hair loss severity score on Sinclair scale was 19.51% in spironolactone group compared to 28.20% in bicalutamide group at 24 weeks, which was statistically significant. On global photographic assessment, marked improvement was seen in bicalutamide group compared to spironolactone group (p = 0.139).
Our study, though limited by its retrospective design and small sample size, showed that bicalutamide has greater efficacy and better safety profile in comparison to spironolactone in the treatment of FPHL.
女性型脱发（FPHL）的特征是头皮毛发密度降低、毛发变细以及毛囊进行性缩小。
比较螺内酯与比卡鲁胺治疗女性型脱发（FPHL）的安全性和疗效。
研究设计为回顾性，纳入所有年龄在 18 至 50 岁之间、符合 FPHL 标准的合格女性。我们从数据库中确定了 120 名符合纳入和排除标准的患者，并将患者分为两组，A 组患者每天服用 100mg 螺内酯，B 组患者每天服用 50mg 比卡鲁胺，两组患者均同时使用 2%米诺地尔局部治疗。在治疗开始后大约 24 周对患者进行分析。
螺内酯组在 Sinclair 量表上脱发严重程度评分的平均降低率为 19.51%，而比卡鲁胺组为 28.20%，这在统计学上有显著差异。在全球照片评估中，比卡鲁胺组的改善程度明显优于螺内酯组（p=0.139）。
我们的研究虽然受到回顾性设计和样本量小的限制，但表明与螺内酯相比，比卡鲁胺在治疗 FPHL 方面具有更好的疗效和安全性。
